Effects of oral nicorandil on myocardial damage, left ventricular cardiac function, and adverse reactions in patients with slow/no-reflow phenomenon during PCI for acute ST-elevation myocardial infarction
Zeyuan FAN,Xinwen JIAN,Hanhua JI
DOI: https://doi.org/10.3969/j.issn.1002-266X.2017.23.031
2017-01-01
Abstract:Objective To evaluate the effects of oral nicorandil after percutaneous coronary interventions (PCI) in reducing myocardial damage and improving left ventricular cardiac function as well as reducing adverse events in patients with slow/no-reflow phenomenon during PCI for acute ST-segment elevation myocardial infarction (STEMI).Methods Totally 110 patients with the slow/no-reflow phenomenon during PCI for STEMI were randomly classified into the observation group (n=55) and control group (n=55).Based on their conditions, patients in the two groups were given secondary coronary prevention drugs including aspirin, clopidogrel, angiotensin converting enzyme inhibitors, angiotensin receptor antagonists, β blockers, statins, ect.Moreover, patients in the observation group were administered oral nicorandil (5 mg, tid) for 30 days.The serum creatine kinase (CK) and creatine kinase isoenzyme (CK-MB) were detected by immunofluorescence at the admission of hospital, and 6, 14, 18, 24, and 48 h after PCI.The levels of plasma brain natriuretic peptide (BNP) were detected by immunoradiometric assay at the admission of hospital and 24 h, 72 h, 7 d and 30 d after PCI.Left ventricular end-diastolic diameter (LVEDD), left ventricular end-diastolic diameter (LVESD), and left ventricular ejection fraction (LVEF) were measured at the admission of hospital, and 7 d, 30 d after PCI.The incidence of malignant arrhythmia, severe heart failure, complications, death of acute myocardial infarction, new myocardial infarction, and target vessel revascularization (TVR) were recorded within 30 days after PCI.Results In the observation group, there were 28 patients (50.91%), 38 patients (69.09%), 54 patients (98.18%) with ECG-related lead elevation ST segment drop> 50% peak at immediate moment, 72 h, and 30 d after PCI, respectively, while in the control group, there were 24 patients (43.64%), 34 patients (61.82%), 49 cases (89.09%) with ECG-related lead elevation ST segment drop> 50% peak, respectively.The incidence of decrease in ECG related lead elevation ST segment drop> 50% peak at immediate moment, 72 h, 30 d after PCI was significantly higher in the observation group as compared with that of the control group (all P<0.05).The peak levels of CK and CK-MB after PCI within 24 h in the observation group and control group were statistically different between the two groups (1205 IU/L vs.1520 IU/L, 192 ug/L vs.238 ug/L, both P<0.05).BNP, LVEDD, and LVESD within 30 days after PCI were significantly lower in the observation group (P<0.05), whereas LVEF levels were higher than those of the control group (P<0.05).The above indicators within 7 days were not statistically different between the two groups (all P>0.05).Within 30 days after PCI, there were 12 (21.82%) of malignant arrhythmia, 8 (14.55%) of severe heart failure, 0 of complication for acute coronary syndrome, 0 of death, 5(9.09%) of new myocardial infarction, 0 of TVR in the control group, while there were 4 (7.27%) of malignant arrhythmia, 2 (3.64%) of severe heart failure, 0 of complication for acute coronary syndrome, 0 of death, 4(7.27%) of new myocardial infarction, 0 of TVR in the observation group.The incidence of malignant arrhythmia and serious heart failure within 30 days after PCI was significantly lower in the observation group than in the control group (both P<0.05).Conclusion For patients with slow/no-reflow phenomenon during PCI for STEMI, oral nicorandil may reduce myocardial damage, improve left ventricular cardiac function, and decrease the incidence of malignant arrhythmia and serious heart failure within 30 days after PCI.